Drug
prasugrel or ticagrelor
prasugrel or ticagrelor is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_4
2
67%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Other(1)
Detailed Status
Completed1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 42 (66.7%)
Trials by Status
completed133%
recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_4
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
NCT05681702
unknownphase_4
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
NCT04981041
completedphase_3
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
NCT01515345
Clinical Trials (3)
Showing 3 of 3 trials
NCT05681702Phase 4
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
NCT04981041Phase 4
Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI
NCT01515345Phase 3
Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3